LRF & NuRD modulators / Syros, Pfizer - LARVOL DELTA

GBT and Syros partner to discover, develop and commercialize novel therapies for sickle cell disease and beta thalassemia (Syros Press Release) - "Global Blood Therapeutics, Inc....and Syros Pharmaceuticals, Inc....today announced that they have entered into a collaboration to discover, develop and commercialize novel therapies for sickle cell disease (SCD) and beta thalassemia....Under the terms of the agreement, GBT will pay Syros $20 million upfront and fund up to $40 million in preclinical research...Syros could receive up to $315 million in option exercise, development, regulatory, commercialization and sales-based milestones...mid- to high-single digit royalties on sales of products resulting from the collaboration."

Licensing / partnership